Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors

Gregory S. Calip, PharmD, MPH, PhD, Wan-Ju Lee, MS, Todd A. Lee, PharmD, PhD, Glen T. Schumock, PharmD, MBA, PhD, Brian C.-H. Chiu, PhD

Blood (2015) 126 (23): 2653.

https://doi.org/10.1182/blood.V126.23.2653.2653

Published: 2015

Journal Articles

Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma

Gregory S. Calip, PharmD, MPH, PhD, Wan-Ju Lee, MS, Todd A. Lee, PharmD, PhD, Glen T. Schumock, PharmD, MBA, PhD, Brian C.-H. Chiu, PhD

Blood (2015) 126 (23): 2954.

https://doi.org/10.1182/blood.V126.23.2954.2954

Published: 2015

Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Andrei R. Shustov, MD, Wyndham H Wilson, MD, PhD, Anne W Beaven, MD, Kerry J. Savage, MD, MSc, Kenneth R. Carson, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sindhu Cherian, MD, Ted A. Gooley, PhD, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3032.

https://doi.org/10.1182/blood.V122.21.3032.3032

Published: 2013

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, David P. Stensma, MD, Chin Y. Li, MD, Antje Hoering, PhD, Jacob B. Allred, MS, Heather L. Powell, MS, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2576.

https://doi.org/10.1182/blood.V106.11.2576.2576

Published: 2005

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, David P. Steensma, MD, Chin Y. Li, MD, Antje Hoering, PhD, Heather Powell, Ayalew Tefferi, MD

Blood (2004) 104 (11): 1520.

https://doi.org/10.1182/blood.V104.11.1520.1520

Published: 2004

NARROW

Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors

Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors

Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (PET Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Etanercept (“PET regimen”) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only